Yan Jie-yu, Wang Mao-qiang, Liu Feng-yong, Wang Zhi-jun, Duan Feng, Song Peng
Department of Interventional Radiography, General Hospital of PLA, Beijing, China.
Zhonghua Yi Xue Za Zhi. 2012 Nov 6;92(41):2893-6.
To evaluate the efficiency and safety of transcatheter arterial embolization (TAE) for treatment of focal nodular hyperplasia (FNH).
From January 2005 to December 2010, super selective TAE was performed for 21 patients with FNH. The patients consisted of 16 men and 5 women with age range of 16 to 44 years (mean age, 28 ± 12). Liver contrast enhancement CT and ultrasonography (US) were performed in all patients, dynamic contrast enhancement MRI was performed in 17 patients. All patients underwent percutaneous needle biopsies and the diagnosis of FNH was proven histologically. The indications for TAE were patients with progressive increase in size of FNH, who were not candidates for surgical treatment, or who refused for surgery. Embolic materials used in this series included emulsion of iodized oil and bleomycin and polyvinyl alcohol particle (PVA). Follow-up examinations included the routine blood tests, liver and renal function tests, US, CT or MRI.
Eighteen patients (85.7%) had a single solitary focus and 3 (14.3%) had multiple foci. The diameter of the mass varied from 3.5 cm to 9.5 cm with a mean of 5.5 cm (5.5 ± 3.0 cm). All patients presented angiographically with characteristic findings, such as feeding artery that was distributed with a spinning wheel appearance, an extensive hypervascular mass, without arterio-venous shunt or portal vein invasion. A single session of TAE was performed in all patients. Technical success of TAE was achieved in all cases. No major complications were encountered in any of our patients. All patients were regularly followed up ranging from 1 to 6 years (3.5 ± 2.0) and they were healthy without recurrence. Marked reduction in the size of the FNH without arterial blood supply was found in 16 patients, and almost complete resolution of the FNH was observed in 6 patients.
TAE is a safe and effective therapy for the management of patients with FNH. TAE could control FNH very well and even could be considered as a radical treatment.
评估经导管动脉栓塞术(TAE)治疗局灶性结节性增生(FNH)的有效性和安全性。
2005年1月至2010年12月,对21例FNH患者实施超选择性TAE。患者包括16例男性和5例女性,年龄范围为16至44岁(平均年龄28±12岁)。所有患者均行肝脏对比增强CT和超声检查(US),17例患者行动态对比增强MRI检查。所有患者均接受经皮穿刺活检,FNH诊断经组织学证实。TAE的适应证为FNH大小逐渐增大、不适合手术治疗或拒绝手术的患者。本系列使用的栓塞材料包括碘化油与博来霉素乳剂和聚乙烯醇颗粒(PVA)。随访检查包括血常规、肝肾功能检查、US、CT或MRI。
18例患者(85.7%)有单个病灶,3例(14.3%)有多个病灶。肿块直径3.5至9.5 cm,平均5.5 cm(5.5±3.0 cm)。所有患者血管造影均有特征性表现,如供血动脉呈车轮状分布、广泛的高血运肿块,无动静脉分流或门静脉侵犯。所有患者均接受单次TAE治疗。TAE在所有病例中均取得技术成功。所有患者均未发生重大并发症。所有患者定期随访1至6年(3.5±2.0年),均健康无复发。16例患者FNH大小明显缩小且无动脉血供,6例患者FNH几乎完全消退。
TAE是治疗FNH患者的一种安全有效的方法。TAE能很好地控制FNH,甚至可被视为一种根治性治疗。